GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures.

Compared to the rest of the cohort, this subgroup had a lower HFEM-to-CM ratio ( p = 0.033), younger age at onset ( p < 0.005), higher baseline MMD ( p < 0.001) and MHD ( p < 0.001), more frequent medication overuse ( p < 0.021), a higher number of prior treatment failures ( p < 0.001) – including a trend toward significance for onabotulinumtoxinA ( p = 0.050), and higher rates of psychiatric comorbidities ( p = 0.004) (Supplementary Table 3).

also in 3,729 other papers